Brainstorm cell therapeutics announces type a meeting with fda granted for nurown®

New york , dec. 27, 2022 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the u.s. food and drug administration (fda) has granted a type a meeting to discuss the contents of a refusal to file letter previously issued regarding the company's new biologics license application (bla) for nurown® for the treatment of als. the type a meeting has been scheduled to occur on january 11, 2023.
BCLI Ratings Summary
BCLI Quant Ranking